Patient trial and appeal board upholds validity of Shire’s patent
Posted: 6 October 2016 | | No comments yet
The Patent Trial and Appeal Board (PTAB) found that the patent was valid in light of the challenges put forward by the petitioner…
The petition seeking to institute inter partes review (IPR) was filed with the US Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) in April of 2015 by the Coalition For Affordable Drugs (CFAD) II L.L.C. Fund. The PTAB found that the patent was valid in light of the challenges put forward by the petitioner.
Shire is pleased with the decision and will continue to vigorously defend its patents to protect the “innovation and value Shire products bring to patients”.
Lialda remains the only once-daily mesalamine product indicated for both the induction of remission of mild to moderate ulcerative colitis and for the maintenance of remission of UC. There have not been any approvals of generic versions of Lialda.